BRPI0909378A2 - métodos para tratar distúrbios usando antagonista seletivo de nmda subtipo nr2b - Google Patents
métodos para tratar distúrbios usando antagonista seletivo de nmda subtipo nr2bInfo
- Publication number
- BRPI0909378A2 BRPI0909378A2 BRPI0909378A BRPI0909378A BRPI0909378A2 BR PI0909378 A2 BRPI0909378 A2 BR PI0909378A2 BR PI0909378 A BRPI0909378 A BR PI0909378A BR PI0909378 A BRPI0909378 A BR PI0909378A BR PI0909378 A2 BRPI0909378 A2 BR PI0909378A2
- Authority
- BR
- Brazil
- Prior art keywords
- antagonist
- methods
- treating disorders
- nr2b subtype
- selective nr2b
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4008708P | 2008-03-27 | 2008-03-27 | |
| PCT/EP2009/002241 WO2009118187A1 (en) | 2008-03-27 | 2009-03-26 | Methods for treating disorders using nmda nr2b-subtype selective antagonist |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0909378A2 true BRPI0909378A2 (pt) | 2015-10-06 |
Family
ID=40910288
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0909378A BRPI0909378A2 (pt) | 2008-03-27 | 2009-03-26 | métodos para tratar distúrbios usando antagonista seletivo de nmda subtipo nr2b |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20110053951A1 (pt) |
| EP (1) | EP2254580A1 (pt) |
| JP (3) | JP2011516417A (pt) |
| KR (1) | KR20100135847A (pt) |
| CN (1) | CN101977606A (pt) |
| AU (1) | AU2009228660B2 (pt) |
| BR (1) | BRPI0909378A2 (pt) |
| CA (1) | CA2719749A1 (pt) |
| IL (1) | IL207835A0 (pt) |
| MX (1) | MX2010009649A (pt) |
| NZ (1) | NZ588698A (pt) |
| RU (1) | RU2499598C2 (pt) |
| WO (1) | WO2009118187A1 (pt) |
| ZA (1) | ZA201006587B (pt) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6042968B2 (ja) | 2012-04-20 | 2016-12-14 | ユセベ ファルマ ソシエテ アノニム | パーキンソン病の処置方法 |
| US11232319B2 (en) * | 2014-05-16 | 2022-01-25 | The Trustees Of The University Of Pennsylvania | Applications of automatic anatomy recognition in medical tomographic imagery based on fuzzy anatomy models |
| JP6618525B2 (ja) * | 2014-08-15 | 2019-12-11 | ヤンセン ファーマシューティカルズ，インコーポレーテッド | ピラゾール類 |
| DK3180329T3 (da) | 2014-08-15 | 2020-04-06 | Janssen Pharmaceuticals Inc | Triazoler som nr2b receptorinhibitorer |
| WO2016196513A1 (en) | 2015-06-01 | 2016-12-08 | Rugen Holdings (Cayman) Limited | 3,3-difluoropiperidine carbamate heterocyclic compounds as nr2b nmda receptor antagonists |
| KR20180026760A (ko) | 2015-07-09 | 2018-03-13 | 얀센 파마슈티카 엔.브이. | 치환된 4-아자인돌 및 glun2b 수용체 조절제로서의 이의 용도 |
| SG11201806750WA (en) | 2016-02-10 | 2018-09-27 | Janssen Pharmaceutica Nv | Substituted 1,2,3-triazoles as nr2b-selective nmda modulators |
| US10487055B2 (en) | 2016-06-01 | 2019-11-26 | Rhode Island Board Of Education | Diindole compounds useful in treatment of nervous system disorders |
| TW201819376A (zh) | 2016-10-06 | 2018-06-01 | 比利時商健生藥品公司 | 經取代之１Ｈ－咪唑並［４，５－ｂ］吡啶－２（３Ｈ）－酮及其作為ＧＬＵＮ２Ｂ受體調節劑之用途 |
| US11000526B2 (en) | 2016-11-22 | 2021-05-11 | Rugen Holdings (Cayman) Limited | Treatment of autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders |
| US11447503B2 (en) | 2019-06-14 | 2022-09-20 | Janssen Pharmaceutica Nv | Pyridine carbamates and their use as GLUN2B receptor modulators |
| US10732235B2 (en) * | 2018-03-29 | 2020-08-04 | Siemens Healthcare Gmbh | Magnetic resonance method and apparatus using atlas-based masking for quantitative susceptibility mapping |
| MA52244A (fr) | 2018-04-04 | 2021-02-17 | Janssen Pharmaceutica Nv | Pyridine et pyrimidines substituées et leur utilisation en tant que modulateurs du récepteur glun2b |
| CN114008052A (zh) | 2019-06-14 | 2022-02-01 | 詹森药业有限公司 | 取代的吡唑并-吡嗪以及它们作为GluN2B受体调节剂的用途 |
| KR20220020915A (ko) | 2019-06-14 | 2022-02-21 | 얀센 파마슈티카 엔.브이. | GluN2B 수용체 조절제로서의 피라진 카르바메이트 및 이들의 용도 |
| EP3983073A1 (en) | 2019-06-14 | 2022-04-20 | Janssen Pharmaceutica NV | Substituted pyrazolo[4,3-b]pyridines and their use as glun2b receptor modulators |
| EP3982958A1 (en) | 2019-06-14 | 2022-04-20 | Janssen Pharmaceutica NV | Substituted heteroaromatic pyrazolo-pyridines and their use as glun2b receptor modulators |
| PE20220386A1 (es) | 2019-06-14 | 2022-03-18 | Janssen Pharmaceutica Nv | Amidas de pirazolo-piridina sustituidas y su uso como moduladores del receptor glun2b |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU717140B2 (en) * | 1996-03-08 | 2000-03-16 | F. Hoffmann-La Roche Ag | Use of 4-phenyl-3,6-dihydro-2H-pyridyl derivatives as NMDA receptor subtype blockers |
| US5985936A (en) * | 1997-12-18 | 1999-11-16 | Forbes Medi-Tech, Inc. | Method of preventing and delaying onset of Alzheimer's disease and composition therefor |
| US6015824A (en) * | 1998-02-10 | 2000-01-18 | Hoffmann-La Roche Ag | Pyrrolidine and piperidine derivatives and treatment of neurodegenerative disorders |
| TWI254043B (en) * | 1999-06-08 | 2006-05-01 | Hoffmann La Roche | Ethanesulfonyl-piperidine derivatives having good affinity to N-methyl-D-aspartate (NMDA) receptor |
| DE60007697T2 (de) * | 1999-07-21 | 2004-12-09 | F. Hoffmann-La Roche Ag | Triazolderivate |
| EP1278728B1 (en) * | 2000-04-20 | 2004-08-25 | F. Hoffmann-La Roche Ag | Pyrrolidine and piperidine derivatives and their use for the treatment of neurodegenerative disorders |
| US6432985B2 (en) * | 2000-04-25 | 2002-08-13 | Hoffmann-La Roche Inc. | Neuroprotective substituted piperidine compounds with activity as NMDA NR2B subtype selective antagonists |
| WO2002028814A2 (en) * | 2000-10-06 | 2002-04-11 | Regents Of The University Of California | Nmda receptor channel blocker with neuroprotective activity |
| US7005432B2 (en) * | 2002-05-16 | 2006-02-28 | Hoffman-La Roche Inc. | Substituted imidazol-pyridazine derivatives |
| JP2009503520A (ja) * | 2005-07-29 | 2009-01-29 | リージェンツ オブ ザ ユニバーシティ オブ ミネソタ | ベータアミロイド受容体及びその使用 |
-
2009
- 2009-03-26 WO PCT/EP2009/002241 patent/WO2009118187A1/en active Application Filing
- 2009-03-26 BR BRPI0909378A patent/BRPI0909378A2/pt not_active IP Right Cessation
- 2009-03-26 RU RU2010143864/15A patent/RU2499598C2/ru not_active IP Right Cessation
- 2009-03-26 CN CN2009801104274A patent/CN101977606A/zh active Pending
- 2009-03-26 MX MX2010009649A patent/MX2010009649A/es active IP Right Grant
- 2009-03-26 NZ NZ588698A patent/NZ588698A/en not_active IP Right Cessation
- 2009-03-26 EP EP09724248A patent/EP2254580A1/en not_active Withdrawn
- 2009-03-26 KR KR1020107023896A patent/KR20100135847A/ko not_active Application Discontinuation
- 2009-03-26 CA CA2719749A patent/CA2719749A1/en not_active Abandoned
- 2009-03-26 JP JP2011501153A patent/JP2011516417A/ja active Pending
- 2009-03-26 US US12/919,804 patent/US20110053951A1/en not_active Abandoned
- 2009-03-26 AU AU2009228660A patent/AU2009228660B2/en not_active Ceased
-
2010
- 2010-08-26 IL IL207835A patent/IL207835A0/en unknown
- 2010-09-14 ZA ZA2010/06587A patent/ZA201006587B/en unknown
-
2014
- 2014-02-05 JP JP2014020051A patent/JP2014098018A/ja active Pending
-
2015
- 2015-12-03 JP JP2015236571A patent/JP2016094430A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2010009649A (es) | 2010-12-17 |
| AU2009228660B2 (en) | 2012-11-29 |
| JP2016094430A (ja) | 2016-05-26 |
| NZ588698A (en) | 2012-06-29 |
| KR20100135847A (ko) | 2010-12-27 |
| RU2499598C2 (ru) | 2013-11-27 |
| ZA201006587B (en) | 2012-02-29 |
| JP2014098018A (ja) | 2014-05-29 |
| RU2010143864A (ru) | 2012-05-10 |
| EP2254580A1 (en) | 2010-12-01 |
| CA2719749A1 (en) | 2009-10-01 |
| JP2011516417A (ja) | 2011-05-26 |
| IL207835A0 (en) | 2010-12-30 |
| CN101977606A (zh) | 2011-02-16 |
| US20110053951A1 (en) | 2011-03-03 |
| AU2009228660A1 (en) | 2009-10-01 |
| WO2009118187A1 (en) | 2009-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0909378A2 (pt) | métodos para tratar distúrbios usando antagonista seletivo de nmda subtipo nr2b | |
| BR112012025101A2 (pt) | compostos antagonistas seletivos de receptor nk-3, composição farmacêutica e métodos para uso em distúrbios mediados por receptores nk-3 | |
| HK1212883A1 (zh) | 治療眼部疾病的方法 | |
| IL248652A0 (en) | Methods, compositions and devices for facilitating re-creation | |
| BRPI0912362A2 (pt) | antagonista do receptor nmda para o tratamento de transtornos neuropsiquiátricos | |
| BRPI0922046A2 (pt) | dispositivo de reprodução, método de reprodução e programa para reprodução estereoscópica | |
| EP2083857A4 (en) | METHOD FOR TREATING INTERFERENCE IN CONNECTION WITH MICA | |
| BRPI0818424A2 (pt) | Método para produzir de nanofibras, e, pano | |
| EP2323681A4 (en) | METHODS OF TREATING VIRAL CONDITIONS | |
| BRPI0810071A2 (pt) | Método para determinação do risco inicial de glaucoma | |
| GB2467710B (en) | Methods for treating social disorders | |
| EP2318010A4 (en) | TREATMENT OF VARIOUS DISORDERS USING TRKB AGONISTS | |
| DK2244628T3 (da) | Patientdata-sensorapparat | |
| BRPI0914680A2 (pt) | método para produção de dispositivos de distribuição | |
| EP2331097A4 (en) | METHOD FOR TREATING CNS DISEASES | |
| BRPI0914393A2 (pt) | "método para caracterização de fitoquímicos" | |
| DE102008010351B8 (de) | Vorrichtung zum Pastillieren | |
| BRPI0820406A2 (pt) | Métodos para identificar aumento de antagonistas do receptor nmda | |
| EP2387402A4 (en) | METHOD FOR THE TREATMENT OF INFLAMMATORY DISORDERS WITH 2,4-PYRIMIDINIAMIN COMPOUNDS | |
| ES2451508T8 (es) | Proceso de acervación múltiple simultánea | |
| BRPI0909659A2 (pt) | tratamento para distúrbios relacionados oculares | |
| BRPI0919599A2 (pt) | aparelho para jogar jogos de azar | |
| BRPI0919310A2 (pt) | aparelho para fazer medições em poços, e método para fazer medições em poços. | |
| BRPI1014007A2 (pt) | aparelho para seleção de suspensões de fibra. | |
| ES1067730Y (es) | Dispositivo autoblocante para persiana |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25D | Requested change of name of applicant approved |
Owner name: EVOTEC INTERNATIONAL GMBH (DE) |
|
| B25G | Requested change of headquarter approved |
Owner name: EVOTEC INTERNATIONAL GMBH (DE) |
|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |